|Bid||1.220 x 0|
|Ask||1.270 x 0|
|Day's range||1.230 - 1.280|
|52-week range||0.590 - 1.425|
|PE ratio (TTM)||N/A|
|Earnings date||19 Feb. 2018 - 23 Feb. 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||1.18|
The Sirtex Medical Limited (ASX:SRX) share price pushed higher on Wednesday after the Federal Court approved the takeover by CDH Genetech and China Grand Pharmaceutical and Healthcare. What now?
Today, I will be analyzing Mayne Pharma Group Limited’s (ASX:MYX) recent ownership structure, an important but not-so-popular subject among individual investors. The impact of a company’s ownership structure affects bothRead More...
The Mayne Pharma Group Ltd (ASX:MYX) share price has rocketed 14% higher to $1.20 following the release of its full year results...
Mayne Pharma Group Limited (ASX:MYX) is a small-cap stock with a market capitalization of AU$1.32b. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies,Read More...
Companies such as Propel Funeral Partners and Jumbo Interactive have a significantly positive future outlook on the basis of their profitability and returns. Investors seeking to enhance their portfolio shouldRead More...
Drugs manufacturer Mayne Pharma is still feeling the impact of tough competition and lower prices in the generic drugs market in the US, but expects the release of new drugs and restructuring initiatives will boost the company's financial performance. Chief executive Scott Richards says the company's first half is expected to be "soft" but that a range of initiatives is already yielding benefits. Shares in Mayne Pharma dropped 1.5 cents, or 2.4 per cent, to 61 cents.
Mayne Pharma's revenue for the first four months of the financial year dropped 12 per cent due to price deflation in the US generic marketplace. Chief executive Scott Richards says group revenue to the ...